|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.700 GBX | +0.65% |
|
-8.33% | +92.50% |
| 02:55pm | Poolbeg Pharma Activates First Site for Clinical Trial of Lead Asset | MT |
| 12:51pm | Poolbeg Pharma Announces Successful Site Activation For POLB 001 TOPICAL Clinical Trial | CI |
Company Valuation: Poolbeg Pharma PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 47.5 | 30.25 | 45.25 | 35.5 | 27.89 | 53.94 |
| Change | - | -36.32% | 49.59% | -21.55% | -21.44% | 93.42% |
| Enterprise Value (EV) 1 | 47.5 | 14.06 | 33.08 | 27.68 | 20.18 | 51.99 |
| Change | - | -70.41% | 135.32% | -16.33% | -27.1% | 157.7% |
| P/E Ratio | -12.8x | -6.44x | -11.5x | -6.12x | -4.26x | -9.22x |
| PBR | - | 1.65x | 3.02x | 3.83x | 2.8x | 19.1x |
| PEG | - | -0.2x | 0.7x | -0.1x | 0.2x | 0.8x |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | -2.83x | -7.1x | -4.61x | -3.72x | -9.28x |
| EV / EBIT | - | -2.82x | -7.06x | -4.53x | -3.68x | -8.81x |
| EV / FCF | - | -2.83x | -7.26x | -5.8x | -4.17x | -8.81x |
| FCF Yield | - | -35.3% | -13.8% | -17.3% | -24% | -11.3% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0074 | -0.0094 | -0.0079 | -0.0116 | -0.0094 | -0.0083 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - |
| EBITDA 1 | - | -4.96 | -4.66 | -5.997 | -5.417 | -5.6 |
| EBIT 1 | - | -4.986 | -4.686 | -6.111 | -5.476 | -5.9 |
| Net income 1 | -2.336 | -4.686 | -3.931 | -5.79 | -5.695 | -5.75 |
| Net Debt 1 | - | -16.19 | -12.17 | -7.824 | -7.713 | -1.95 |
| Reference price 2 | 0.0950 | 0.0605 | 0.0905 | 0.0710 | 0.0400 | 0.0765 |
| Nbr of stocks (in thousands) | 5,00,000 | 5,00,000 | 5,00,000 | 5,00,000 | 6,97,200 | 7,05,104 |
| Announcement Date | 02/03/22 | 30/03/23 | 30/04/24 | 20/05/25 | 28/04/26 | - |
1GBP in Million2GBP
Estimates
P/E Ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.22x | - | -9.28x | - | 7.23Cr | |
| 32.3x | 8.39x | 25.37x | 0.06% | 5.48TCr | |
| 16.24x | 4.87x | 10.58x | 1.85% | 4.33TCr | |
| -16.97x | 3.74x | -6.55x | -.--% | 2.18TCr | |
| -34.28x | 11.45x | -33.43x | -.--% | 1.99TCr | |
| 19.37x | 3.76x | 9.77x | -.--% | 1.57TCr | |
| 21.29x | 4.28x | 14.15x | -.--% | 1.53TCr | |
| 16.63x | 4.79x | 11.24x | -.--% | 1.32TCr | |
| 38.34x | 14.76x | 43.34x | 0.17% | 1.16TCr | |
| -419.07x | 28.52x | -3179.37x | -.--% | 1.19TCr | |
| Average | -33.54x | 9.40x | -311.42x | 0.23% | 2.08TCr | |
| Weighted average by Cap. | -11.05x | 8.10x | -173.06x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- POLB Stock
- Valuation Poolbeg Pharma PLC
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition